Peripheral arterial disease - A cardiovascular time bomb

British Journal of Diabetes and Vascular Disease

Volumn 7, Issue 5, 2007, Pages 236-239

  Belch, Jill ^a   Stansby, Gerry ^b   Shearman, Cliff ^c   Brittenden, Julie ^d   Dugdill, Shiela ^b   Fowkes, Gerry ^e   Jarvis, Sarah ^f   McCann, Terrie ^g   Mimnagh, Andrew ^h   Monkman, David ⁱ   Morrell, Jonathan ^j  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b FREEMAN HOSPITAL   (United Kingdom)

^c UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^d UNIVERSITY OF ABERDEEN   (United Kingdom)

^e UNIVERSITY OF EDINBURGH   (United Kingdom)

^f Richford Gate Medical Practice   (United Kingdom)

^g The Circulation Foundation   (United Kingdom)

^h Eastview Surgery   (United Kingdom)

ⁱ East Barnet Health Centre   (United Kingdom)

^j NONE   (United Kingdom)

more..

Author keywords

Cardiovascular disease; Peripheral arterial disease; Quality and outcomes framework

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT;

ALGORITHM; ANKLE BRACHIAL INDEX; ARTERY DISEASE; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL ASSESSMENT; CLINICAL PROTOCOL; DIET RESTRICTION; DYSLIPIDEMIA; EXERCISE; GLYCEMIC CONTROL; HEART DEATH; HUMAN; HYPERTENSION; LIFESTYLE MODIFICATION; MORTALITY; PERIPHERAL VASCULAR DISEASE; PRACTICE GUIDELINE; PREVALENCE; PRIMARY MEDICAL CARE; QUALITY OF LIFE; RISK ASSESSMENT; RISK FACTOR; RISK MANAGEMENT; SMOKING CESSATION; THROMBOSIS; UNITED KINGDOM;

EID: 35848955189     PISSN: 14746514     EISSN: None     Source Type: Journal    
DOI: 10.1177/14746514070070050701     Document Type: Article

References (23)

1. The Coronary Heart Disease National Service Framework - Shaping the Future, Progress Report for 2006. Standards 3 & 4: Preventing CHD in high risk. Department of Health 2006.
2. JBS2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice, http://heart.bmjjournals.com/cgi/reprint/91/suppl_5/ v1?ijkey=PbMmm2L5wGIMU&keytype=ref&siteid=bmjjournals (Accessed February 2006).
3. Belch J, Topol E, Agnelli G, Bertrand M. Critical issues in peripheral arterial disease detection and management. Arch Intern Med 2003; 163:884-92.
4. Norgren L, Hiatt WR, Dormandy JA et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Surg Vol 33, Supplement 1, 2007.
5. Appraisal Consultation Document: Clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events.http://www.nice.org.uk/page.aspx?o=105159 (Accessed September 2007).
6. Fowkes FG, Housley E, Cawood EHH et al. Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. Int J Epidemiol 1991;20:384-92.
7. Dumville JC, Lee AJ, Smith FB, Fowkes FG. The health-related quality of life of people with peripheral arterial disease in the community: the Edinburgh Artery Study. Br J Gen Prac 2004;54:826-31.
8. Aronow WS, Ahn C. Prevalence of coexistence of coronary artery disease, peripheral arterial disease, and atherothrombotic brain infarction in men and women? 62 years of age. Am J Cardiol 1994;74:64-5.
9. Tierney S, Fennessy F, Hayes DB. ABC of arterial and vascular disease. Secondary prevention of peripheral vascular disease. BMJ 2000; 320: 1262-5.
10. Criqui MH, Langer RD, Fronek A et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992;326: 381-6.
11. Steg PG, Bhatt DL, Wilson PWF et al. R. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA 2007; 297:1197-206.
12. American Cancer Society, Cancer Facts and Figures - 1997 http://www.cancer.org/downloads/STT/F&F97.pdf (Accessed January 2007).
13. Mister R, Flather M, Delahunty N et al. Coronary heart disease in patients with intermittent claudication [abstract]. Heart 2004;Suppl:A81.
14. Peripheral Arterial Diseases Antiplatelet Consensus Group. Antiplatelet therapy in peripheral arterial disease. Consensus statement. Eur J Vasc Endovasc Surg 2003;26:1-16.
15. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324: 71-86.
16. Collins R, Armitage J, Parish S, Sleight P, Peto R; Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo controlled trial. Lancet 2004;363:757-67.
17. Gent M, et al. Effectiveness of Clopidogrel Versus Aspirin in Preventing Acute Myocardial Infarction in Patients With Symptomatic Atherothrombosis (CAPRIE Trial). Lancet 1996;348:1329-39.
18. Scottish Intercollegiate Guideline Network (SIGN). Diagnosis and management of peripheral arterial disease. A National Clinical Guideline. October 2006.
19. Grundy S, Pasternak R, Greenland P et al. Assessment of Cardiovascular Risk by Use of Multiple-Risk-Factor Assessment Equations. A Statement for Healthcare Professionals from the American Heart Association and the American College of Cardiology. Circulation 1999;100:1481-92.
20. Duvall WL, Vorchheimer DA. Multi-bed vascular disease and atherothrombosis: scope of the problem. J Thromb Thrombolysis 2004; 17:51-61.
21. Michael H, Criqui Vargo V, Denemberg JO et al. Ethnicity and Peripheral Arterial Disease: The San Diego Population Study. Circulation 2005;112;2703-07.
22. Belch J, Stansby G et al. Peripheral arterial disease: still on the periphery? BMJ 2006;532:1213.
23. Target PAD Group Management Algorithm for primary care. August 2006.